NT 0002
Alternative Names: NT-0002Latest Information Update: 09 Mar 2024
At a glance
- Originator Nucleome Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple sclerosis
Most Recent Events
- 18 Jan 2024 Early research in Multiple sclerosis in United Kingdom (unspecified route) (Nucleome Therapeutic pipeline, January 2024)